福泰制药 VRTX 深 沪
等待开盘 10-14 09:30:00 美东时间
407.37
-0.420
-0.10%
华盛通- 最 高409.4699
- 今 开404.21
- 成交量 81.36万股
- 最 低 402.58
- 昨 收 407.79
- 总市值 1042.87亿
- 52周最高 519.88
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 362.50
- 委 比 -46.74%
- 总股本 2.56亿
- 历史最高 519.88
- 量 比 0.60
- 振 幅 1.69%
- 历史最低 26.50
- 每 手 1
- 风险率 42.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation has committed up to $11 million in additional funding to support the development of 4D-710, a genetic medicine for cystic fibrosis (CF) lung disease, with an initial tranche of $7.5 million. This funding will accelerate the advancement of 4D-710, including a second dosing cohort in Phase 1, Phase 2 enrollment with a pivotal dose of 2.5E14 vg, and preparation for Phase 3. The CF Foundation has now invested nearly $32...
10-13 12:00
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
美联储降息再迎大消息，纳指生科创年内新高，纳指生物科技ETF(513290)强势收涨6.22%，连续16日获资金加仓，“吸金”近7300万元
隔夜（10月8日）美股收盘，美股三大指数涨跌不一，纳指涨1.12%，标普500指数涨0.58%，两者均创收盘新高，道指收平。纳斯达克生物科技指数收涨0.89%...
10-09 17:58
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
vTv Therapeutics has appointed four distinguished scientists to its Scientific Advisory Board to guide the clinical development of cadisegliatin, an oral adjunctive therapy for type 1 diabetes now in Phase 3 trials. The board includes leaders in diabetes research, clinical trial design, and regulatory science, aiming to provide strategic input on the advancement of cadisegliatin. The company is committed to advancing this innovative treatment, cu...
10-09 12:00
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
Aardvark Therapeutics expanded the Phase 3 HERO trial for ARD-101 to include patients aged 10 and older, aligning with FDA guidance. This broadens eligibility for treating hyperphagia in Prader-Willi Syndrome (PWS), a rare disease causing insatiable hunger. The drug, an agonist of taste receptors, reduces hunger by stimulating gut hormone release. More patients may benefit from early intervention, with top-line data expected in Q3 2026.
10-08 12:00
Vertex and Kintsugi Launch AI-Powered Tax Automation Solution: Kintsugi powered by Vertex
Vertex Inc. and Kintsugi have launched "Kintsugi powered by Vertex," an AI-native tax automation solution designed to simplify tax compliance for small and mid-sized businesses. The platform automates key functions like nexus monitoring, registration, tax calculation, and filing, providing real-time dashboards and seamless integration with financial systems. Aimed at delivering scalability, ease of use, and precision, this collaboration extends V...
10-08 12:00
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Verrica Pharmaceuticals will present VP-315, an investigational oncolytic peptide for basal cell carcinoma, at the SITC 40th Annual Meeting. Both oral and poster presentations will discuss Phase 2 trial results assessing local immune activation post-treatment. The oral presentation is on November 5-9, 2025, in Maryland, with a 12:46–12:54 p.m. ET slot. VP-315, which induces immunogenic cell death, has shown promising immune responses in trials an...
10-07 20:05
Virtu Financial Congratulates Women in Finance Award Recipient Pegah Esmaeili
Virtu Financial's Pegah Esmaeili, Head of the Nordic Region, has been awarded the Excellence in Sales & Trading (Equities) at Markets Media’s European Women in Finance Awards. Recognized for her leadership in driving Virtu’s growth across the Nordic region, Pegah has also spearheaded Virtu’s successful Winter Conference in Stockholm. Virtu Financial, a leading global financial services firm, provides execution services, data, analytics, and conne...
10-07 17:15
VirTra Wins $4.8 Million U.S. Department of State Award to Support Law Enforcement Training in Colombia
VirTra, Inc. (Nasdaq: VTSI) announced a $4.8 million award from the U.S. Department of State's INL for providing seven V-ST PRO systems with Recoil Kits and Advanced Skills Magazines in Colombia. This expands VirTra's presence in Colombia, aligning with U.S. goals for law enforcement training and capacity building. The V-ST PRO simulators, featuring realistic recoil and advanced marksmanship training, will be deployed nationwide. VirTra's CEO hig...
10-07 12:00
